Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg Formulation

NCT05027308 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05027308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg Formulation
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
January 4, 2022
Completion date
September 27, 2023
Enrollment
3 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

short bowel syndrome